What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2023-03-10 compared with 2022-02-28 · 45 added, 28 removed, 92 unchanged (44% of the section changed)

5 unchanged sentences

The following information sets forth the names,

ages, and positions of our executive officers as of February 24, 2022.

ages, and positions of our executive officers as of March 10, 2023.

Positions and Offices Held

6 unchanged sentences

Chief Technology Officer

Chief Product Officer

Set forth below is a brief description of the

9 unchanged sentences

Febbo was a co-founder of, and from September 2013 to September 2015 served as Chief

Executive Officer of, Digital Capital Network, Inc.

a transaction platform for institutional and accredited investors.

Mr Febbo was a

co-founder of, and from January 1999 to September 2015 was Chief Executive Officer of, MedPanel, LLC, a provider of market intelligence

Executive Officer of, Digital Capital Network, Inc., a transaction platform for institutional and accredited investors.

a co-founder of, and from January 1999 to September 2015 was Chief Executive Officer of, MedPanel, LLC, a provider of market intelligence

and communications for the pharmaceutical, biomedical, and medical device industries.

5 unchanged sentences

a development stage medical device company focused on the design, development and eventual commercialization of an innovative insulin

pump , and as a director of Augmedix, Inc.

AUGX), a provider of automated medical

documentation and data services.

In addition, Mr.

Febbo has been a board member of the United Nations Association of Greater Boston, a resource for the citizens

of Greater Boston on the broad agenda of critical global issues addressed by the UN and its agencies, since 2004.

Febbo has been a board member of the United Nations Association of Greater Boston, a

resource for the citizens of Greater Boston on the broad agenda of critical global issues addressed by the UN and its agencies, since

On January 29, 2018, FINRA accepted a Letter of

5 unchanged sentences

From August 2012 to October 2015, Mr.

Febbo was the Financial and Operations Principal

(FinOp) for a registered broker-dealer, Merriman Capital, Inc.

Febbo was the Financial and Operations Principal (FinOp)

for a registered broker-dealer, Merriman Capital, Inc.

(“Merriman”).

During certain months while Mr.

Febbo was FinOp,

FINRA found that certain of Merriman’s net capital filings with FINRA were inaccurate because of the method by which Merriman calculated

Febbo was FinOp, FINRA

found that certain of Merriman’s net capital filings with FINRA were inaccurate because of the method by which Merriman calculated

net capital and that, when corrected, it was retroactively determined that Merriman had operated below its minimum net capital requirements.

23 unchanged sentences

(dba Charles River

Associates), a global consulting firm that offers economic, financial, and strategic expertise to major law firms, corporations, accounting

firms, and governments around the world.

Associates) (NASDAQ:

CRAI), a global consulting firm that offers economic, financial, and strategic expertise to major law firms, corporations,

accounting firms, and governments around the world.

From May 2004 to November 2004, Ms.

Odence-Ford was a member of the GTC Law Group, LLP, a law

firm specializing in the business affairs of companies in the high tech and biotech industries.

Prior to joining the GTC Law Group, Ms.

Odence-Ford worked on the legal teams of Bank of America Corporation/Fleet Boston Financial Corporation from November 2002 to May 2004,

and Akamai Technologies, Inc.

from October 1999 to November 2002.

Odence-Ford began her legal career in private practice at Mintz,

Levin, Cohn, Ferris, Glovsky and Popeo, PC, where she advised public and private companies on corporate matters.

Odence-Ford was a member of the GTC Law Group,

LLP, a law firm specializing in the business affairs of companies in the high tech and biotech industries.

Prior to joining the GTC Law

Odence-Ford worked on the legal teams of Bank of America Corporation/Fleet Boston Financial Corporation (NYSE:

BAC) from November

2002 to May 2004, and Akamai Technologies, Inc.

AKAM) from October 1999 to November 2002.

Odence-Ford began her legal career

in private practice at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC, where she advised public and private companies on corporate

Edward Stelmakh

1 unchanged sentence

Officer and Chief Operating Officer on October 11, 2021.

He has served as Senior Vice President, Chief Financial Officer and Chief Operating

Officer of Otsuka America Pharmaceuticals Inc.

(“Otsuka”), a US division of a Japanese global healthcare enterprise, since

Previously, he held various positions at Otsuka including Senior Vice President and Chief Financial Officer (December 2017

– March 2020) and Vice President and Chief Financial Officer (December 2015 – November 2017).

Prior to joining Otsuka, from

March 2010 to December 2015, Mr.

Prior to joining the Company, Mr.

Stelmakh served as Senior Vice President, Chief

Financial Officer and Chief Operating Officer of Otsuka America Pharmaceuticals Inc.

(“Otsuka”), a US division of a Japanese

global healthcare enterprise, since April 2020.

Previously, he held various positions at Otsuka including Senior Vice President and Chief

Financial Officer (December 2017 – March 2020) and Vice President and Chief Financial Officer (December 2015 – November 2017).

From March 2010 to December 2015, Mr.

Stelmakh worked at Covance, a division of LabCorp, Inc., as Vice President, Finance, Clinical Development

19 unchanged sentences

subsidiary, providing medical office electronic data interchange services.

Besch joined the Company on May 24, 2021 as

SVP Product Strategy & Innovation and became the Company’s Chief Product Officer in October 2022.

Prior to joining the Company, from

January 2018 to May 2021, Dr.

Besch was the Vice President over Payor and Market Access Solutions for Clarivate (previously Decision Resources

Group (DRG)), a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical,

biotech, medical device, healthcare provider and payer, and managed care companies.

Prior to Clarivate, from January 2012 to June 2017,

Besch was a co-founder and the Chief Product Officer for Rx Savings Solution, a company which helps members

and payers reduce prescription drug costs through a combination of clinical technology, transparency, member engagement and concierge

Besch holds a PharmD and MBA from Creighton University and practiced as a pharmacist for the Walgreens Boots Alliance

corporation from 2007 through 2013.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings